Insmed (INSM) Non-Current Assets (2010 - 2026)
Insmed's (INSM) quarterly Non-Current Assets came in at $462.7 million in Q1 2026, up 15.66% year-on-year from $400.0 million in Q1 2025, and down 1.63% quarter-over-quarter from $470.4 million in Q4 2025.
Insmed (INSM) Non-Current Assets (2010 - 2026) Analysis & Trends
Insmed's Non-Current Assets history runs 17 years deep, the most recent figure standing at $462.7 million for Q1 2026.
- On a quarterly basis, Non-Current Assets rose 15.66% year-over-year to $462.7 million in Q1 2026; TTM through Mar 2026 was $1.8 billion, a 10.11% increase from a year earlier, with the FY2025 full-year figure at $470.4 million, up 16.55% from the prior year.
- Non-Current Assets eased to $462.7 million in Q1 2026 per INSM's latest filing, from $470.4 million in the prior quarter.
- Across five years, Non-Current Assets topped out at $470.4 million in Q4 2025 and bottomed at $362.7 million in Q3 2022.
- The 5-year median for Non-Current Assets is $398.3 million (2023), against an average of $403.2 million.
- Biggest YoY gain for Non-Current Assets was 107.52% in 2022; the steepest drop was 5.76% in 2022.
- Year by year, Non-Current Assets stood at $383.1 million in 2022, then climbed by 4.63% to $400.8 million in 2023, then rose by 0.7% to $403.6 million in 2024, then increased by 16.55% to $470.4 million in 2025, then dropped by 1.63% to $462.7 million in 2026.
- Per Business Quant, the three latest INSM Non-Current Assets figures stand at $462.7 million (Q1 2026), $470.4 million (Q4 2025), and $428.9 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 21.65 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 5.83 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 1.95 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 3.95 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 14.75 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 22.66 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | 289.41 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 1.96 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 285.82 Mn |
| 10 | Insmed | 23.26 Bn | 22.03 Bn | 258.54 Mn | 462.69 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 462.69 Mn |
| Dec 31, 2025 | 470.35 Mn |
| Sep 30, 2025 | 428.93 Mn |
| Jun 30, 2025 | 398.28 Mn |
| Mar 31, 2025 | 400.04 Mn |
| Dec 31, 2024 | 403.57 Mn |
| Sep 30, 2024 | 403.13 Mn |
| Jun 30, 2024 | 391.93 Mn |
| Mar 31, 2024 | 400.37 Mn |
| Dec 31, 2023 | 400.77 Mn |
| Sep 30, 2023 | 398.30 Mn |
| Jun 30, 2023 | 386.72 Mn |
| Mar 31, 2023 | 388.65 Mn |
| Dec 31, 2022 | 383.05 Mn |
| Sep 30, 2022 | 362.65 Mn |
| Jun 30, 2022 | 378.63 Mn |
| Mar 31, 2022 | 397.18 Mn |
| Dec 31, 2021 | 406.47 Mn |
| Sep 30, 2021 | 352.79 Mn |
| Jun 30, 2021 | 191.59 Mn |